Asthma treatment

http://www.healasthma.com – . TWC – TWC (USA) – The Weather Channel – - Part TIME START Lennox.Looking pretty nice.As we head io the middle portion of the country, Kansas city degrees in metro north mall.Dallas you’re looking at at the north park center and if you’re going to be making your way out to seattle, some rain is going to be across north gate.Your temperature of degrees.Now with more on what you can expect across the northeast, here is bill.>Kristin, … . TWC – TWC (USA) – The Weather Channel – TIME START The winds were whipping up and sees a big change since yesterday.I can’t tell you how many feet we have lost, I’m really not sure about that but if it comes up over the dune, we’re in trouble.st.John’s county is aware the weather this season will play havoc with erosion and allowing some homeowners to install special retaining walls like this but jones and others say that’s not the way to… Merck Announces Strong Financial Results for the First Quarter Merck & Co., Inc. Media Amy Rose, – - or Investor Graeme Bell, – - Merck & Co., Inc – Company Posts First-Quarter Earnings Per Share (EPS) of Cents, Excluding Restructuring Charges, and Reported First-Quarter EPS of Cents — Solid Performance of ZOCOR, SINGULAIR and Vaccines Plus Strong Results From Partnerships Drive Earnings — Merck Raises Full-Year Guidance and now Anticipates EPS Range of . to… . FD (FAIR DISCLOSURE) WIRE – Q Merck & Co., Inc. Earnings Conference Call – Final OPERATOR Good morning, ladies and gentlemen. And welcome to the Merck & Company first quarter earnings conference call. At this time, all participants have been placed on a listen-only mode. And the floor will be open for your questions following the presentation. It is now my pleasure to introduce your host, Mr. Mark Stejbach, Senior Director of Investor Relations. Sir, the floor is yours.MARK STEJBACH, SENIOR DIRECTOR OF IR, MERCK & COMPANY OK. Thank… . Record, The (Kitchner, Ontario, Canada) – Asthma pill now OK’d for young children A new treatment option is available for young children with asthma.Health Canada has approved a new chewable tablet that has been shown to reduce breathlessness and wheezing.Sold under the brand name Singulair, the cherry-flavoured tablet is taken once a day before bedtime. It has been approved for use in children two to five years old.Singulair has been on the market for several years for teenagers and adults.The medication, developed by Merck Frosst Canada, is a lot easier… . FDA APPROVES ASTHMA DRUG FOR YOUNG CHILDREN Top of the Morning WASHINGTON – Children as young as can try a once-a-day cherry-flavored pill to help prevent asthma attacks, the Food and Drug Administration decided Monday.The drug Singulair, manufactured by Merck & Co., already is used by adults and older children.But the FDA approved a slightly lower-dose pill Monday intended for children ages to , making Singulair the first asthma prevention therapy for children so young.Singulair does not treat asthma… . FDA APPROVES ASTHMA CONTROLLER FOR KIDS Top of the Morning Children as young as can try a once-a-day cherry-flavored pill to help prevent asthma attacks, the Food and Drug Administration decided Monday.The drug Singulair, manufactured by Merck & Co., already is used by adults and older children.But the FDA approved a slightly lower-dose pill Monday intended for children ages to , making Singulair the first asthma prevention therapy for children so young. Singulair does not treat asthma attacks -… . Daily Telegraph (Sydney, Australia) – ASTHMA LIFELINE A new asthma pill which was launched in Britain this week and is being considered for release in Australia could drastically reduce the number of asthma attacks suffered by many children and adults.Singulair is one of a family of drugs called leukotriene antagonists which have been on the US market for a year under the brand name Accolate. If given the go-ahead by the Therapeutic Goods Administration, Singulair could be widely available in Australia next year.”It is a very… . FD (FAIR DISCLOSURE) WIRE – Merck Annual Business Briefing – Final EVA BORATTO, VP, INVESTOR RELATIONS, MERCK Good morning, everyone, and welcome. I’m Eva Boratto, Vice President — Investor Relations at Merck. We appreciate you joining us here today to discuss Merck’s plans to position our Company for future success. During the past year we’ve had the opportunity to meet with many of you and it’s certainly a pleasure to see you here today at our corporate headquarters. For those of you who are here in… . FD (FAIR DISCLOSURE) WIRE – Merck Annual Business Briefing – Final EVA BORATTO, VP, INVESTOR RELATIONS, MERCK Good morning, everyone, and welcome. I’m Eva Boratto, Vice President — Investor Relations at Merck. We appreciate you joining us here today to discuss Merck’s plans to position our Company for future success. During the past year we’ve had the opportunity to meet with many of you and it’s certainly a pleasure to see you here today at our corporate headquarters. For those of you who are here in… –